Observational Study of YUTIQ 0.18 mg Implant for Treating Chronic Non-infectious Uveitis in Adults Aged 18 to 70

What this Trial Is About

Researchers are evaluating the effectiveness of YUTIQ4 0.18 mg intravitreal implant for managing chronic non-infectious uveitis. This observational study divides participants into two groups one receiving the YUTIQ implant and the other receiving traditional therapy with glucocorticoids alone or combined with immunosuppressants. The study aims to assess anti-inflammatory effects and relapse reduction over time. Participants in the YUTIQ group receive a 0.18 mg implant injected into the designated study eye and are followed for up to 36 months. The traditional therapy group receives glucocorticoids or glucocorticoids plus immunosuppressants and is also monitored for up to 36 months. The study compares outcomes between these two groups throughout the follow-up period. Participants will undergo assessments including best corrected visual acuity BCVA, anterior chamber and vitreous inflammation, optical coherence tomography OCT, and corticosteroid dose changes. Researchers will track these outcomes at regular visits over 12 to 36 months to evaluate changes in vision, inflammation, and recurrence rates. Safety and side effects will also be monitored during the study period.

A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis